Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者,在42个月的随访中证明了持续的生存益处

2020-02-17 不详 MedSci原创

百时美施贵宝公司今天宣布了CheckMate -214三期研究的最新结果,该研究评估了PD-1单抗Opdivo(nivolumab)加CTLA-4单抗Yervoy(ipilimumab)与舒尼替尼的组合在先前未经治疗的晚期或转移性肾细胞癌(RCC)中随访42个月的疗效。

百时美施贵宝公司今天宣布了CheckMate -214三期研究的最新结果,该研究评估了PD-1单抗Opdivo(nivolumab)加CTLA-4单抗Yervoy(ipilimumab)与舒尼替尼的组合在先前未经治疗的晚期或转移性肾细胞癌(RCC)中随访42个月的疗效。

随访42个月,Opdivo和Yervoy的组合仍显示出较高的总体生存率(OS)、客观缓解率(ORR),缓解持续时间(DOR)和完全缓解率(CR)。Opdivo联合Yervoy的安全性与先前的发现一致,并且延长随访时间未发生新的安全信号或与药物相关的死亡。数据于2020年2月15日星期六在American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium中进行了介绍。

与单独用舒尼替尼相比,Opdivo加Yervoy联合舒尼替尼从中期和差风险(IP)和意向性治疗(ITT,即所有随机化)中观察到明显益处。

CheckMate -214研究的最新结果表明,接受 Opdivo 加 Yervoy 治疗的患者中有50%在42个月时还活着,而接受舒尼替尼治疗的患者中有39%存活。根据独立评估,使用 Opdivo 加 Yervoy 治疗的患者的完全缓解率保持并持续超过80%。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
    2020-02-19 119337457
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
    2020-02-19 gostraight
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978943, encodeId=e09719e89431b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Apr 09 14:07:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945882, encodeId=7e301945882af, content=<a href='/topic/show?id=8ca65983e4f' target=_blank style='color:#2F92EE;'>#晚期或转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59837, encryptionId=8ca65983e4f, topicName=晚期或转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Dec 17 05:07:00 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303089, encodeId=8112130308979, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365815, encodeId=3e3e136581527, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420310, encodeId=bee31420310a4, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93430, encryptionId=5ed393430f3, topicName=转移性肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da33575570, createdName=zhangyxzsh, createdTime=Wed Feb 19 03:07:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]

相关资讯

难治性晚期或复发性卵巢癌患者的III期试验:Opdivo(Nivolumab)未能改善总生存率

ONO制药公司宣布,在静脉输注抗PD-1单克隆抗体(Opdivo,Nivolumab)治疗难治性晚期或复发性卵巢癌患者的III期试验(ONO-4538-23)中,Opdivo没有显著改善总生存率(OS)(主要终点)。

Opdivo与Yervoy的联合未能在晚期黑色素瘤研究中达到所有主要终点

百时美施贵宝近日报道说,一项III期研究比较了PD-1抑制剂Opdivo(nivolumab)和抗CTLA-4抗体Yervoy(ipilimumab)联合治疗某些已切除的高危黑色素瘤患者,但试验结果未能达到其中的一项主要终点。

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

百时美施贵宝公司宣布,在CheckMate -9LA这项重要的III期临床试验中,PD-1单抗Opdivo(nivolumab)与低剂量CTLA-4单抗Yervoy(ipilimumab)联合使用,与化学相比治疗晚期非小细胞肺癌患者,该试验达到了总体生存率(OS)的主要终点。

BMS的PD-1单抗Opdivo:未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

Bristol-Myers Squibb宣布,在新诊断为O6-MGMT甲基化的多形性胶质母细胞瘤患者中,将Opdivo(nivolumab)加入标准治疗未能显着改善无进展生存期(PFS)。该公司表示将继续观察III期临床试验CheckMate-548整体生存率(OS)的数据。

Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌

ONO制药和Bristol-Myers Squibb近日宣布,两家公司已提交了Opdivo(nivolumab)联合Yervoy(ipilimumab)治疗不可切除、晚期或复发性非小细胞肺癌(NSCLC)的申请。

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗,展开优先审查

FDA已经开始对未接受过治疗且没有EGFR或ALK突变的NSCLC患者进行PD-1抑制剂Opdivo(nivolumab)联合BMS低剂量CTLA4抑制剂Yervoy(ipilimumab)进行优先审查,并于5月15日前作出判决。